SI1725548T1 - Postopki in intermediati za pripravo inhibitorjev asparagin-acetal-kaspaze - Google Patents

Postopki in intermediati za pripravo inhibitorjev asparagin-acetal-kaspaze

Info

Publication number
SI1725548T1
SI1725548T1 SI200531959T SI200531959T SI1725548T1 SI 1725548 T1 SI1725548 T1 SI 1725548T1 SI 200531959 T SI200531959 T SI 200531959T SI 200531959 T SI200531959 T SI 200531959T SI 1725548 T1 SI1725548 T1 SI 1725548T1
Authority
SI
Slovenia
Prior art keywords
intermediates
processes
preparation
caspase inhibitors
aspartic
Prior art date
Application number
SI200531959T
Other languages
English (en)
Inventor
Gerald J. Tanoury
Minzhang Chen
Andrew D. Jones
Philip L. Nyce
Martin Trudeau
David J. Guerin
John R. Snoonian
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of SI1725548T1 publication Critical patent/SI1725548T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/04—Formation or introduction of functional groups containing nitrogen of amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
SI200531959T 2004-03-12 2005-03-11 Postopki in intermediati za pripravo inhibitorjev asparagin-acetal-kaspaze SI1725548T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55248004P 2004-03-12 2004-03-12
EP05728092.7A EP1725548B1 (en) 2004-03-12 2005-03-11 Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
PCT/US2005/008251 WO2005090334A2 (en) 2004-03-12 2005-03-11 Processes and intermediates for the preparation of aspartic acetal caspase inhibitors

Publications (1)

Publication Number Publication Date
SI1725548T1 true SI1725548T1 (sl) 2015-05-29

Family

ID=34962478

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200531945T SI2399915T1 (sl) 2004-03-12 2005-03-11 Postopek in intermediati za pripravo inhibitorjev asparagin-acetal-kaspaze
SI200531959T SI1725548T1 (sl) 2004-03-12 2005-03-11 Postopki in intermediati za pripravo inhibitorjev asparagin-acetal-kaspaze
SI200531941T SI2399916T1 (sl) 2004-03-12 2005-03-11 Postopek in intermediati za pripravo inhibitorjev asparagin-acetal-kaspaze

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200531945T SI2399915T1 (sl) 2004-03-12 2005-03-11 Postopek in intermediati za pripravo inhibitorjev asparagin-acetal-kaspaze

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200531941T SI2399916T1 (sl) 2004-03-12 2005-03-11 Postopek in intermediati za pripravo inhibitorjev asparagin-acetal-kaspaze

Country Status (22)

Country Link
US (4) US7381827B2 (sl)
EP (3) EP2399916B1 (sl)
JP (2) JP4898658B2 (sl)
KR (2) KR101135765B1 (sl)
CN (3) CN102225936B (sl)
AR (1) AR048008A1 (sl)
AU (1) AU2005223767B2 (sl)
BR (1) BRPI0508609B8 (sl)
CA (3) CA2843066C (sl)
DK (3) DK2399916T3 (sl)
ES (3) ES2532967T3 (sl)
HK (2) HK1105955A1 (sl)
HU (1) HUE024556T2 (sl)
IL (3) IL178003A (sl)
PL (4) PL1725548T3 (sl)
PT (3) PT2399915E (sl)
RU (2) RU2433127C2 (sl)
SG (2) SG150547A1 (sl)
SI (3) SI2399915T1 (sl)
TW (3) TW201200508A (sl)
WO (1) WO2005090334A2 (sl)
ZA (1) ZA200607605B (sl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AR045596A1 (es) 2003-09-05 2005-11-02 Vertex Pharma Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
WO2005085236A2 (en) * 2004-02-27 2005-09-15 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
JP4848367B2 (ja) * 2004-05-15 2011-12-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ｉｃｅインヒビターを使用した発作の処置
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CA2643688A1 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
EP1993994A2 (en) 2006-03-16 2008-11-26 Vertex Pharmceuticals Incorporated Deuterated hepatitis c protease inhibitors
CA2669917A1 (en) 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines as chemokine receptor antagonists
GEP20125645B (en) * 2007-02-27 2012-09-25 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
MX2009009176A (es) 2007-02-27 2009-09-28 Vertex Pharma Inhibidores de serina-proteasas.
JP5443360B2 (ja) 2007-08-30 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶体およびそれを含む医薬組成物
WO2010017408A1 (en) 2008-08-06 2010-02-11 The Buck Institute For Age Research Caspase inhibitors and uses thereof
US9113848B2 (en) * 2010-02-03 2015-08-25 Covidien Lp Surgical retrieval apparatus
JP5769655B2 (ja) * 2012-03-30 2015-08-26 ユニ・チャーム株式会社 吸収性物品
CN103193572B (zh) * 2013-04-07 2015-06-17 山东大学 一种拉唑类化合物单一对映体的分离方法
WO2018112626A1 (en) 2016-12-23 2018-06-28 Andrea Leblanc Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
BE1008343A3 (nl) 1994-05-06 1996-04-02 Dsm Nv Bidentaat fosfineligand
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
ATE195923T1 (de) * 1995-11-09 2000-09-15 Akzo Pq Silica Vof Kompaktiertes natriumsilicat
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
AU739496B2 (en) 1996-09-12 2001-10-11 Idun Pharmaceuticals, Incorporated Novel tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes
ATE310528T1 (de) 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
IL128940A0 (en) 1996-09-12 2000-02-17 Idun Pharmaceuticals Inc C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases and pharmaceutical compositions containing them
US5968927A (en) 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
AU738341B2 (en) 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
CA2268086A1 (en) 1996-10-11 1998-04-23 Warner-Lambert Company Sulfonamide interleukin-1.beta. converting enzyme inhibitors
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
FR2766188B1 (fr) 1997-07-15 2000-02-11 Hoechst Marion Roussel Inc Nouveau procede de preparation de derives amines d'alkyloxy furanone, composes issus de ce procede et utilisation de ces composes
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
ATE388139T1 (de) 1997-12-18 2008-03-15 Boehringer Ingelheim Pharma Pyridone als hemmer der sh2-domäne der src- familie
AU1466399A (en) 1998-01-20 1999-08-02 Basf Aktiengesellschaft N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6 -dihydro-1-pyrimidinyl)aceto- xyl)-l-aspartic acid aldehyde as an (in vivo) inhibitor of interleukin-1beta converting enzyme (ice)
JP4594520B2 (ja) 1998-03-19 2010-12-08 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼのインヒビター
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
AU765462B2 (en) 1999-03-16 2003-09-18 Merck Frosst Canada & Co. Gamma-ketoacid dipeptides as inhibitors of caspase-3
CA2367340A1 (en) 1999-03-16 2000-09-21 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
CN1176941C (zh) 1999-04-09 2004-11-24 西托维亚公司 Caspase抑制剂及其应用
JP4749640B2 (ja) 1999-07-19 2011-08-17 メルク フロスト カナダ リミテツド ピラジノン、このような化合物を含む組成物
EP1163208B1 (en) 1999-08-06 2004-05-12 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
KR20020033777A (ko) 1999-08-27 2002-05-07 추후보정 치환된 α-히드록시 산 카스파제 억제제 및 이의 용도
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
EP1268425B1 (en) 2000-03-29 2008-01-23 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
AU2001251165A1 (en) 2000-04-03 2001-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
IL152393A (en) * 2000-04-24 2008-03-20 Vertex Pharma Process for making aspartic acid acetal derivatives
TWI291462B (en) 2000-04-25 2007-12-21 Daiichi Sankyo Co Ltd Hydrate crystal of neuraminic acid compound
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US7053057B2 (en) 2000-05-23 2006-05-30 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
JP2003535865A (ja) 2000-06-07 2003-12-02 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびその使用
KR100904788B1 (ko) 2000-07-21 2009-06-25 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드
EP1317454B1 (en) 2000-09-13 2011-05-25 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
AU2002232541A1 (en) 2000-11-21 2002-06-03 Vertex Pharmaceuticals Incorporated Imidazole and benzimidazole caspase inhibitors and uses thereof
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
WO2002085899A1 (en) 2001-04-19 2002-10-31 Vertex Pharmaceuticals Incorporated Heterocyclyldicarbamides as caspase inhibitors
EP1392289A2 (en) 2001-05-23 2004-03-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
DE60217114T2 (de) 2001-07-11 2007-10-25 Vertex Pharmaceuticals Inc., Cambridge Verbrückte bizyklische serinproteaseinhibitoren
EP1436248A2 (en) 2001-10-09 2004-07-14 Vertex Pharmaceuticals Incorporated Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
US7410956B2 (en) 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
WO2003088917A2 (en) 2002-04-19 2003-10-30 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
US7138395B2 (en) 2002-06-10 2006-11-21 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
US7041696B2 (en) 2002-06-17 2006-05-09 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
AR040350A1 (es) 2002-06-28 2005-03-30 Vertex Pharma Inhibidores de caspasa y usos de los mismos
CN100366612C (zh) 2002-12-20 2008-02-06 沃泰克斯药物股份有限公司 4-氧代-3-(1-氧代-1h-异喹啉-2-基乙酰氨基)-戊酸酯和酰胺衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
WO2005085236A2 (en) * 2004-02-27 2005-09-15 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2012072151A (ja) 2012-04-12
PT2399915E (pt) 2015-03-30
ES2532967T3 (es) 2015-04-06
EP1725548B1 (en) 2015-01-14
DK2399915T3 (en) 2015-03-09
PT1725548E (pt) 2015-04-16
TW201200508A (en) 2012-01-01
TWI398426B (zh) 2013-06-11
TW200602341A (en) 2006-01-16
US20110071298A1 (en) 2011-03-24
CN1950364B (zh) 2011-06-08
EP2399915A1 (en) 2011-12-28
IL218487A0 (en) 2012-04-30
BRPI0508609B1 (pt) 2021-03-30
SG150546A1 (en) 2009-03-30
EP2399916A1 (en) 2011-12-28
DK2399916T3 (en) 2015-03-02
EP2399916B1 (en) 2014-12-10
CA2768700C (en) 2014-04-29
BRPI0508609B8 (pt) 2021-05-25
PL1725548T3 (pl) 2015-08-31
KR20070006835A (ko) 2007-01-11
CA2843066C (en) 2016-06-07
SI2399916T1 (sl) 2015-05-29
TW201247594A (en) 2012-12-01
SI2399915T1 (sl) 2015-05-29
EP2399915B1 (en) 2014-12-17
BRPI0508609A (pt) 2007-07-31
ZA200607605B (en) 2009-04-29
TWI399356B (zh) 2013-06-21
IL178003A (en) 2012-04-30
WO2005090334A2 (en) 2005-09-29
CA2843066A1 (en) 2005-09-29
AU2005223767B2 (en) 2011-12-01
JP4898658B2 (ja) 2012-03-21
KR101135765B1 (ko) 2012-04-23
PL381358A1 (pl) 2007-05-28
RU2006136032A (ru) 2008-04-20
RU2433127C2 (ru) 2011-11-10
CA2559303A1 (en) 2005-09-29
CN103467459A (zh) 2013-12-25
EP1725548A2 (en) 2006-11-29
US7834200B2 (en) 2010-11-16
WO2005090334A3 (en) 2005-11-17
IL218488A0 (en) 2012-04-30
CN1950364A (zh) 2007-04-18
US7381827B2 (en) 2008-06-03
KR20110137409A (ko) 2011-12-22
CA2559303C (en) 2013-09-10
US8293929B2 (en) 2012-10-23
SG150547A1 (en) 2009-03-30
IL218487A (en) 2015-08-31
US20130066083A1 (en) 2013-03-14
CA2768700A1 (en) 2005-09-29
US20090048429A1 (en) 2009-02-19
CN102225936B (zh) 2013-09-11
PL2399916T3 (pl) 2015-06-30
ES2532433T3 (es) 2015-03-26
RU2011127174A (ru) 2013-01-10
US20060020016A1 (en) 2006-01-26
AU2005223767A1 (en) 2005-09-29
AR048008A1 (es) 2006-03-15
HUE024556T2 (hu) 2016-02-29
PL2399915T3 (pl) 2015-07-31
CN102225936A (zh) 2011-10-26
JP2007528904A (ja) 2007-10-18
DK1725548T3 (en) 2015-03-23
HK1105955A1 (en) 2008-02-29
HK1163672A1 (en) 2012-09-14
ES2533991T3 (es) 2015-04-16
PT2399916E (pt) 2015-03-17
IL178003A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
HK1105955A1 (en) Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
IL182305A0 (en) Diaminoalkane aspartic protease inhibitors
ITMI20032121A1 (it) Procedimento per la preparazione di imiquimod e suoi intermedi
GB2428296B (en) Enhancing the acqisition and processing of low frequencies for sub-salt imaging
ZA200711085B (en) Processes for the manufacture of rosuvastatin and intermediates
IL187303A0 (en) Methods of prepering 3 - cyano - quinolines and intermediates made thereby
ZA200710342B (en) The preparation and use of compounds as aspartyl protease inhibitors
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
IL176958A0 (en) Compounds and methods of use
IL180359A0 (en) Solid forms of linezolid and processes for preparation thereof
EP1744744A4 (en) BIOACTIVE COMPOUNDS AND METHODS OF USE THEREOF
EP1753708A4 (en) NEW SIRTUIN ACTIVATING COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
EP1856006A4 (en) SIALON CERAMIC AND METHOD OF MANUFACTURE
IL190201A0 (en) Pde inhibitors and combinations thereof for the treatment of urological disorders
AP1986A (en) Detection of diamonds
IL177709A0 (en) Caspase inhibitors and uses thereof
PL1817387T3 (pl) Zastosowanie polisilazanów do nakładania powłok na taśmy metalowe
ZA200705773B (en) Thermocouple assembly and method of use
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
IL187832A0 (en) Methods and intermediates for the preparation of optionally radio- labeled imatinib
SG115828A1 (en) Fluid-ejection device and methods of forming same
GB0504333D0 (en) Treatment of cytokine dysregulation
GB0414120D0 (en) Novel processes and intermediates
ZA200802668B (en) PDE inhibitors and combinations thereof for the treatment of urological disorders
ZA200705455B (en) Silicon compounds and their use